2025 Q4 -tulosraportti
Vain PDF
31 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
34 min sitten34 min sittenOk ok, lets send some Rockets to celebrate the good news ♥️🚀🚀🚀🚀🚀 Good night everyone.
·2 t sittenSince we are a cheering squad, I think it must be acceptable to present one of the professionals who was there's assessment of Circios' presentation:
·2 t sittenI attended many other interesting presentations, but my favorite session was the last one of the conference, "New insights into AAV genome biology," which included a presentation that impressed me the most. This was a presentation from Erik Digman Wiklund from Circio Holding ASA, who presented a new vector that enables powerful circular RNA expression that increases AAV transgene production to such an extent that the dose of viral vectors can be significantly reduced, leading to much lower chances of severe immune response. The session also included a very interesting presentation from Mark Brimble, who showed that host cell DNA encapsulation is not a random process, but rather a skewed, AAV Rep-driven phenomenon.
·2 t sitten🧬 POSSIBLE HISTORIC BREAKTHROUGH AWAITS 🧬 Our man, Wiklund, has presented comprehensive circVec-data at ASGCT in Boston – the world's most important conference in gene and cell therapy. Most importantly: - up to 40x higher gene expression in the heart - up to 50x in the eye - potential for lower doses, better safety, and cheaper treatments Today's AAV gene therapy struggles with high doses and side effects. If circVec can indeed significantly reduce the dosage requirement, it could solve one of the biggest problems in the entire field. It could therefore be an important and historic breakthrough! Circio also states that the technology is generating strong interest among potential partners, and we can look forward to Monday! This is not just “another biotech news item”. This could be the start of something much bigger 🚂 (PS: Make your own choices. Don't use money you can't afford to lose. Do your own research.)
·2 t sitten · MuokattuGenerally rock solid. Remember this is a professional conference. It's not just big pharma that's there. The world's foremost researchers in the field are there. What is delivered and presented must have very high scientific solidity, otherwise one is easily exposed. They have delivered professionally top-notch. It is absolutely crucial for being able to commercialize the technology platform in the next round. The strategy at ASGCT has strictly focused on the gene therapy project. They will extract the commercial opportunities here first. CNS is obviously held back. It is only contractual ties with Big Pharma that are the reason for this. Noted that "muscle tissue" was again listed as "ongoing". It has been completely silent about this for almost 1 year, then it was brought up. CircVec obviously has a general application in all organ and tissue types. It is unique. It is possibly the main message to the world's biotech industry and science. No quick or easy news. Rock-solid quality. That's the only thing that works in the long run. 2 news items are apparently coming in this q2 as I read the presentation. T-cell data and disease construct in the heart. Circio's international standing has been significantly strengthened. It is incredibly important. Trigger is coming. And partners are coming unless the entire technology gets "eaten". As a listed company with dispersed ownership, the company is vulnerable and an easy target.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
31 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 34 min sitten34 min sittenOk ok, lets send some Rockets to celebrate the good news ♥️🚀🚀🚀🚀🚀 Good night everyone.
- ·2 t sittenSince we are a cheering squad, I think it must be acceptable to present one of the professionals who was there's assessment of Circios' presentation:·2 t sittenI attended many other interesting presentations, but my favorite session was the last one of the conference, "New insights into AAV genome biology," which included a presentation that impressed me the most. This was a presentation from Erik Digman Wiklund from Circio Holding ASA, who presented a new vector that enables powerful circular RNA expression that increases AAV transgene production to such an extent that the dose of viral vectors can be significantly reduced, leading to much lower chances of severe immune response. The session also included a very interesting presentation from Mark Brimble, who showed that host cell DNA encapsulation is not a random process, but rather a skewed, AAV Rep-driven phenomenon.
- ·2 t sitten🧬 POSSIBLE HISTORIC BREAKTHROUGH AWAITS 🧬 Our man, Wiklund, has presented comprehensive circVec-data at ASGCT in Boston – the world's most important conference in gene and cell therapy. Most importantly: - up to 40x higher gene expression in the heart - up to 50x in the eye - potential for lower doses, better safety, and cheaper treatments Today's AAV gene therapy struggles with high doses and side effects. If circVec can indeed significantly reduce the dosage requirement, it could solve one of the biggest problems in the entire field. It could therefore be an important and historic breakthrough! Circio also states that the technology is generating strong interest among potential partners, and we can look forward to Monday! This is not just “another biotech news item”. This could be the start of something much bigger 🚂 (PS: Make your own choices. Don't use money you can't afford to lose. Do your own research.)
- ·2 t sitten · MuokattuGenerally rock solid. Remember this is a professional conference. It's not just big pharma that's there. The world's foremost researchers in the field are there. What is delivered and presented must have very high scientific solidity, otherwise one is easily exposed. They have delivered professionally top-notch. It is absolutely crucial for being able to commercialize the technology platform in the next round. The strategy at ASGCT has strictly focused on the gene therapy project. They will extract the commercial opportunities here first. CNS is obviously held back. It is only contractual ties with Big Pharma that are the reason for this. Noted that "muscle tissue" was again listed as "ongoing". It has been completely silent about this for almost 1 year, then it was brought up. CircVec obviously has a general application in all organ and tissue types. It is unique. It is possibly the main message to the world's biotech industry and science. No quick or easy news. Rock-solid quality. That's the only thing that works in the long run. 2 news items are apparently coming in this q2 as I read the presentation. T-cell data and disease construct in the heart. Circio's international standing has been significantly strengthened. It is incredibly important. Trigger is coming. And partners are coming unless the entire technology gets "eaten". As a listed company with dispersed ownership, the company is vulnerable and an easy target.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
31 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 34 min sitten34 min sittenOk ok, lets send some Rockets to celebrate the good news ♥️🚀🚀🚀🚀🚀 Good night everyone.
- ·2 t sittenSince we are a cheering squad, I think it must be acceptable to present one of the professionals who was there's assessment of Circios' presentation:·2 t sittenI attended many other interesting presentations, but my favorite session was the last one of the conference, "New insights into AAV genome biology," which included a presentation that impressed me the most. This was a presentation from Erik Digman Wiklund from Circio Holding ASA, who presented a new vector that enables powerful circular RNA expression that increases AAV transgene production to such an extent that the dose of viral vectors can be significantly reduced, leading to much lower chances of severe immune response. The session also included a very interesting presentation from Mark Brimble, who showed that host cell DNA encapsulation is not a random process, but rather a skewed, AAV Rep-driven phenomenon.
- ·2 t sitten🧬 POSSIBLE HISTORIC BREAKTHROUGH AWAITS 🧬 Our man, Wiklund, has presented comprehensive circVec-data at ASGCT in Boston – the world's most important conference in gene and cell therapy. Most importantly: - up to 40x higher gene expression in the heart - up to 50x in the eye - potential for lower doses, better safety, and cheaper treatments Today's AAV gene therapy struggles with high doses and side effects. If circVec can indeed significantly reduce the dosage requirement, it could solve one of the biggest problems in the entire field. It could therefore be an important and historic breakthrough! Circio also states that the technology is generating strong interest among potential partners, and we can look forward to Monday! This is not just “another biotech news item”. This could be the start of something much bigger 🚂 (PS: Make your own choices. Don't use money you can't afford to lose. Do your own research.)
- ·2 t sitten · MuokattuGenerally rock solid. Remember this is a professional conference. It's not just big pharma that's there. The world's foremost researchers in the field are there. What is delivered and presented must have very high scientific solidity, otherwise one is easily exposed. They have delivered professionally top-notch. It is absolutely crucial for being able to commercialize the technology platform in the next round. The strategy at ASGCT has strictly focused on the gene therapy project. They will extract the commercial opportunities here first. CNS is obviously held back. It is only contractual ties with Big Pharma that are the reason for this. Noted that "muscle tissue" was again listed as "ongoing". It has been completely silent about this for almost 1 year, then it was brought up. CircVec obviously has a general application in all organ and tissue types. It is unique. It is possibly the main message to the world's biotech industry and science. No quick or easy news. Rock-solid quality. That's the only thing that works in the long run. 2 news items are apparently coming in this q2 as I read the presentation. T-cell data and disease construct in the heart. Circio's international standing has been significantly strengthened. It is incredibly important. Trigger is coming. And partners are coming unless the entire technology gets "eaten". As a listed company with dispersed ownership, the company is vulnerable and an easy target.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt